Novel insights into the management of rheumatoid arthritis: one year in review 2023.

Abstract

New evidence from 2022 slightly changed some perspectives for rheumatoid arthritis (RA) management. Real-world data on the efficacy and safety of disease-modifying anti-rheumatic drugs strengthened the importance of tailoring treatment decisions based on patient characteristics. Moreover, the research of response biomarkers to therapy underlined the need for precision medicine and remote care applications showed an innovative outlook that supports a patient-centred approach. New developments in vaccinations led to the release of updated guidelines and to a consistent improvement in the prevention of vaccine-preventable infections. New literature data also reconsidered drug management in RA-associated interstitial lung disease and pregnancy. In this paper, the reviewers aim to present the most relevant studies published during the last year in the field of RA management.

• Authors: Carlo Garaffoni, Antonella Adinolfi, Alessandra Bortoluzzi, Georgios Filippou, Alessandro Giollo, Garifallia Sakellariou, Ettore Silvagni, Silvia Sirotti, Nicola Ughi, Carlo Alberto Scirè
• Journal: Clinical and experimental rheumatology (Clin Exp Rheumatol) Vol. 41 Issue 11 Pg. 2129-2141 (Nov 2023) ISSN: 0392-856X [Print] Italy
• PMID: 37497719 (Publication Type: Journal Article, Review)

Chemical References

• Antirheumatic Agents

Topics

• Female
• Pregnancy
• Humans
• Arthritis, Rheumatoid (drug therapy)
• Antirheumatic Agents (therapeutic use)
• Vaccination